A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)

Inclusion Criteria: * Completion of at least 6 cycles of therapy on BMS clinical protocol CA124-001 or CA124-002 and who continue to derive clinical benefit and are not experiencing intolerable toxicity from the therapy * Karnofsky score of at least 50 for subjects \> 10 years of age; Lansky play scale of at least 50 for children 10 years of age and younger * Recovery to baseline or Grade 1 from toxicities (except alopecia or asthenia) resulting from previous therapies * Males and females, ages 1 - 21 years of age at the time of consent into CA124-001 or CA124-002 Exclusion Criteria: * A serious uncontrolled medical disorder that in the opinion of the Investigator would impair the ability of the subject to receive protocol therapy * Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy, or any other investigational drug while on study * Inadequate bone marrow and renal function * Concurrent receipt of Dilantin®(phenytoin), phenobarbital, primidone, Tegretol®(carbamazepine), Depacon®, Depakene®, Depakote®, and Deproic®(valproic acid)